Allegro’s injectable osteoarthritis treatment generates positive safety results in preclinical studies

Core Insights - Allegro NV has reported positive results from preclinical studies of hydrocelin (ALG-001), an injectable microparticle hydrogel, showing no signs of toxicity over 4 and 13 weeks [1][4][8] - The company plans to initiate a pivotal clinical study in osteoarthritis patients in Belgium later this year [1][2][8] - Hydrocelin is designed to restore the shock-absorbing capacity of synovial fluid in joints, potentially providing pain relief and protecting cartilage [3][5] Company Overview - Allegro NV is a private biomedical company focused on developing treatments for degenerative joint diseases using its proprietary nanotechnology platform, INTRICATE [6] - Hydrocelin is positioned as a potential first-in-class, disease-modifying treatment for osteoarthritis, with clinical studies in humans expected to commence later this year and a commercial launch targeted for 2027 [6] Product Details - Hydrocelin consists of cross-linked microparticles that act as shock absorbers in the synovial fluid, enhancing impact absorption and optimizing load distribution [5] - The treatment is minimally invasive and aims to promote joint homeostasis while providing pain relief and protecting cartilage [5]